BIODEXA PHARMA

• 72110 - Research and experimental development on biotechnology

Biodexa Pharmaceuticals is a biopharmaceutical company developing a pipeline of products aimed at cancers of the brain... eRapa™ is a proprietary oral tablet formulation of rapamycin (sirolimus). Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR is known to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Rapamycin is approved in the US for organ rejection in renal transplantation. It is very poorly water soluble and current formulations exhibit significant variability in systemic plasma levels. Through the use of nanotechnology and pH sensitive polymers, eRapa™ is designed to improve bioavailability and achieve more consistent pharmacokinetics than existing products.

Also known as: Biodexa Pharma Plc, BIODEXA PHARMACEUTICALS PLC

Previous names: MIDATECH PHARMA PLC

Registration numbers: 09216368 (CH)

Primary location: Cardiff United Kingdom